1. In Vivo

Xtent and the Next DES Boom

Safety concerns and a retrenchment in usage have dimmed the luster of drug-eluting stents, but only slightly. If the market is to turn around and, more importantly, serve the kind of patients who really need these devices, a second-generation drug-eluting stent will be needed, one designed specifically for these new patients. And Xtent believe it has the technology to do just that.

by David Cassak

In the fall of 2006, alarming headlines out of the European Society of Cardiology (ESC) meeting in Barcelona ominously asked, "Do drug-eluting stents kill patients?" Data reported at the meeting...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By Jo Shorthouse

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By Jo Shorthouse

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By David Wild

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.